ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag pharma cancer fda genetics genomics

Bugs as Drugs to Boost Cancer Therapy
Danielle Gerhard, PhD | Jan 18, 2024 | 7 min read
Bioengineered bacteria sneak past solid tumor defenses to guide CAR T cells’ attacks.
2022 Top 10 Innovations 
2022 Top 10 Innovations
The Scientist | Dec 12, 2022 | 10+ min read
This year’s crop of winning products features many with a clinical focus and others that represent significant advances in sequencing, single-cell analysis, and more.
Opinion: Talking Genomics
Trevor Quirk | Nov 13, 2012 | 5 min read
The crucial importance of language in the debate over the regulation of direct-to-consumer genetic tests
Avant-Garde Science
Mary Beth Aberlin | Jun 1, 2012 | 3 min read
Why naked mole-rats and experimental gene therapies remind me of groundbreaking artists.
Single Nucleotide Polymorphisms: Big Pharma Hedges its Bets
Eugene Russo | Jul 18, 1999 | 7 min read
SNP CENTRAL: A genetics researcher takes to the bench at the Wellcome Trust's Sanger Centre in Cambridge, England. The sequencing center and its London sponsor provided key leadership in the SNP Consortium, a public-private venture to find and map 300,000 single nucleotide polymorphisms. The Wellcome Trust helped entice 10 pharmaceutical firms to join the consortium by putting up $14 million of the project's estimated $45 million price tag. The Sanger Centre will provide much of the radiation h
Pharma CPR
Brendan Borrell | Dec 1, 2009 | 7 min read
.table { font-family: "Trebuchet MS", Arial, Helvetica, sans-serif; text-align: center; }.drug_table { font-size: 11px; font-family: "Trebuchet MS", Arial, Helvetica, sans-serif; }.drug_table td { padding: 2px; border-left: 1px solid #CCCCCC; }.drug_table tr.even td, .drug_table thead tr td { font-weight: bold; }.drug_table thead tr td { font-size: 13px; color: #62A476; }.drug_table tr.even td { background: #F8E4B9; }.drug_table tr.odd td { bac
PARP Inhibitors Are Improving the Outlook of Hard-to-Treat Cancers
Vicki Brower | Apr 1, 2018 | 9 min read
With three recent FDA approvals, and a number of Phase 3 trials ongoing, the drugs are seeing a surge in interest.
Diagnosing Cancer: A Genomics and Proteomics Approach
Tom Hollon | Sep 21, 2003 | 7 min read
In 1996, Jeff Trent and colleagues published the first paper describing DNA microarrays as tools for pinpointing gene variants underlying various tumor properties.1 Now, as president and scientific director of Translational Genomics Research Institute (TGEN), in Phoenix, Trent is using microarrays to look for gene expression patterns that can be applied to developing diagnostics. The role of microarrays, Trent says, "will be on the discovery side. Testing all 30,000 genes against a diagnosti
Pharma Cooperates to Achieve Precision Medicine
Catherine Offord | Feb 1, 2017 | 7 min read
The challenges of adapting drug development to the age of personalized therapies encourage collaboration among industry players.
Top 10 Innovations 2021
2021 Top 10 Innovations
The Scientist | Dec 1, 2021 | 10+ min read
The COVID-19 pandemic is still with us. Biomedical innovation has rallied to address that pressing concern while continuing to tackle broader research challenges.

Run a Search

ADVERTISEMENT